Memory Loss & Cognitive Decline Treatment
Memory loss and cognitive decline treatment works best when it starts before the damage is irreversible, but by the time most patients receive a diagnosis, years of treatable decline have already passed. At The Neurogenesis Project, Dr. Orr uses precision biomarkers and advanced neuroimaging to detect metabolic brain failure early and treat its causes directly.
Available at our St. Marys, Georgia clinic.
The Problem with Waiting
The standard approach to memory complaints in neurology follows a familiar pattern. The patient reports forgetfulness. The physician administers a brief screening tool like the Montreal Cognitive Assessment. If the score is above the cutoff for impairment, the patient is told that their memory is “within normal limits” and asked to come back in a year. If the score is borderline, a structural MRI is ordered. If the MRI shows no large-vessel strokes or mass lesions, the patient is reassured and sent home.
The problem is that by the time these standard tools detect a change, the underlying disease process has been running for a decade or more. Amyloid plaque deposition in Alzheimer’s disease begins fifteen to twenty years before the first clinical symptoms appear (Jack et al., 2013, The Lancet Neurology). Neuroinflammation and synaptic loss are well established before any screening questionnaire can pick them up. The window for meaningful intervention is not the moment of diagnosis. It is the years before that moment, when the brain is still compensating and the damage is still reversible.
Blood-based biomarkers have changed what is possible. Plasma p-tau217, a phosphorylated tau species, now identifies Alzheimer’s-related pathology with over 95% accuracy compared to PET and CSF standards (Palmqvist et al., 2020, JAMA). This means that clinicians no longer need to wait for a patient to fail a screening test or show atrophy on imaging. The molecular signature of disease is detectable in a blood draw years before clinical decline becomes obvious.
This is the principle behind what we call the Neuroeconomy: cognition is the primary unit of value in a human life. Every year of undetected decline carries a compounding cost—to career performance, to relationships, to independence, to the quality of the years that remain. Treating that decline as an inevitable part of aging, rather than as a measurable and modifiable biological process, is a choice. And it is the wrong one.
What a Precision Evaluation Reveals
Our evaluation begins with structural MRI to measure hippocampal volume, cortical thickness, and white matter integrity. Hippocampal atrophy is one of the earliest structural markers of Alzheimer’s disease and can be quantified years before clinical symptoms emerge. We also use PET scanning to map glucose metabolism across the brain. Regions of hypometabolism in the temporal and parietal lobes are characteristic of early neurodegenerative processes and often appear while the patient is still performing normally on office-based cognitive tests.
Blood-based biomarkers add a molecular layer to the structural and metabolic picture. We measure plasma p-tau217, which reflects tau phosphorylation specific to Alzheimer’s pathology. We also measure neurofilament light chain (NfL), a marker of axonal damage that rises in multiple neurodegenerative conditions. Homocysteine levels indicate methylation status and B-vitamin adequacy, both of which directly affect neuronal health. Brain-derived neurotrophic factor (BDNF) levels tell us about the brain’s capacity for synaptic maintenance and repair. Inflammatory markers including IL-6 and TNF-alpha help identify chronic neuroinflammation that accelerates neuronal loss.
Neurogenomic testing completes the evaluation. We look at genetic variants that affect amyloid clearance (APOE status), methylation pathways (MTHFR and related polymorphisms), detoxification capacity, and neurotransmitter metabolism. These results explain why a given patient is declining at the rate they are, and they inform which therapeutic targets are most likely to produce a measurable response.
The combination of imaging, blood biomarkers, and genomics produces a diagnostic picture that no single test provides alone. Learn more about our imaging capabilities on our brain imaging page.
Our Treatment Approach
Treatment protocols are assembled from several regenerative and metabolic therapies based on each patient’s diagnostic findings. No two protocols are identical because no two patients arrive with the same combination of drivers.
NAD+ IV Therapy
Nicotinamide adenine dinucleotide is the central coenzyme in mitochondrial energy production. Neurons with declining mitochondrial output produce less ATP and accumulate more oxidative damage. IV NAD+ restores the substrate these cells need to maintain metabolic function. Braidy et al. (2019, Antioxidants & Redox Signaling) showed that NAD+ depletion is a consistent feature of age-related neurodegeneration.
Exosome Therapy
Extracellular vesicles derived from mesenchymal stem cells cross the blood-brain barrier and deliver anti-inflammatory cytokines, neurotrophic factors, and regulatory microRNAs to damaged neural tissue. These vesicles modulate the local immune environment and support repair processes in regions where chronic inflammation is driving neuronal loss.
Stem Cell Therapy
Mesenchymal stem cells provide paracrine signaling that reduces neuroinflammation, supports angiogenesis, and promotes trophic factor release in areas of neurodegeneration. A phase I trial by Brody et al. (2023, Nature Medicine) found that intrathecal MSC administration in Alzheimer’s patients was safe and associated with reduced CSF biomarkers of inflammation.
These therapies are delivered together during our Intensive Brain Health Program, a three-to-five-day protocol that combines diagnostics, physician review, and a full course of treatment in a single visit.
Who Should Be Evaluated
Cognitive decline does not begin at a diagnosis. It begins years earlier, in patterns that are measurable if you know where to look.
Early Memory Changes in Your 40s Through 60s
You have noticed that you lose words more often, that names take longer to retrieve, that you re-read paragraphs you used to absorb on the first pass. Your annual physical says everything is fine. These changes may be age-related and benign, or they may be the earliest measurable signal of a process that will accelerate if left unaddressed. Biomarker testing can distinguish between the two.
Family History of Dementia
A first-degree relative with Alzheimer’s disease or another form of dementia increases your own risk by a factor of two to four, depending on the specific genetic and environmental overlap. APOE genotyping, p-tau217 levels, and metabolic imaging can establish your current risk profile and identify modifiable factors before symptoms appear.
Post-Concussion Cognitive Changes
Traumatic brain injury accelerates neurodegenerative pathology. Patients with a history of concussion or repetitive subconcussive exposure often develop cognitive symptoms in their 40s and 50s that would not have appeared until decades later in the absence of injury. Our TBI evaluation overlaps with our cognitive decline workup because the mechanisms are closely related.
Executives & Professionals with Declining Performance
You built a career on the speed and precision of your thinking, and you have noticed that both are slipping. Decisions take longer. Complex problems that you once worked through quickly now require more effort. These changes are not always pathological, but they are always worth measuring. For ongoing cognitive maintenance between clinic visits, we recommend Action Potential Supplements, our targeted supplementation line for brain health.
Related Treatments
Traumatic Brain Injury
TBI and cognitive decline share overlapping mechanisms. Prior head injury accelerates neurodegeneration through chronic neuroinflammation and mitochondrial dysfunction that standard imaging rarely detects.
NAD+ IV Therapy
Restore mitochondrial energy production in neurons with declining metabolic output. NAD+ is the primary substrate for ATP synthesis and a key regulator of sirtuins and DNA repair enzymes involved in neuroprotection.
Exosome Therapy
Extracellular vesicles that cross the blood-brain barrier and deliver anti-inflammatory signals, growth factors, and regulatory microRNAs to regions where neuroinflammation is driving progressive neuronal loss.
What to Expect
Comprehensive neurological history
Estimated time: 30 minutes
Dr. Orr takes a detailed history of your cognitive symptoms, including when they started, how they have progressed, what triggers or worsens them, and how they affect daily function. He also reviews your medical history, medications, sleep, and family history of neurological conditions.
Neurological examination
Estimated time: 30 minutes
Dr. Orr performs a bedside neurological exam assessing memory, language, attention, visuospatial function, motor coordination, reflexes, and cranial nerves. This examination helps localize any neurological deficits and guide further testing.
Cognitive testing battery
Estimated time: 45 minutes
You complete standardized cognitive assessments that quantify performance across multiple domains. These tests provide objective data that Dr. Orr compares to age-matched norms and uses to track changes over time.
Diagnostic workup
Estimated time: 30 minutes
Based on the examination and cognitive test results, Dr. Orr orders targeted diagnostics which may include brain MRI with volumetric analysis, blood biomarkers, EEG, or PET imaging. The specific tests depend on the pattern of decline and the differential diagnosis.
Diagnosis and treatment plan
Estimated time: 30 minutes
Once all results are available, Dr. Orr meets with you to explain the findings, provide a diagnosis when one can be made, and outline a treatment plan. This may include IV therapies, lifestyle interventions, or referral for additional specialty evaluation.
Frequently Asked Questions
When should I worry about memory loss?+
Forgetting where you put your keys is normal. Forgetting entire conversations, getting lost on familiar routes, or having people close to you notice changes in your thinking — those warrant a neurological evaluation.
Read the full answer
Normal aging produces occasional word-finding difficulty and slower recall under time pressure. These are different from the kinds of memory failures that signal pathology. If you are forgetting entire conversations, losing track of familiar routes, struggling to follow multi-step instructions that were previously routine, or if people close to you have commented on changes in your memory or judgment, those patterns warrant evaluation. The earlier a decline is identified, the wider the window for intervention. Waiting until a diagnosis of dementia is made means that substantial neuronal loss has already occurred.
What diagnostic tools do you use to evaluate cognitive decline?+
We use brain MRI, PET scans, blood tests that can detect Alzheimer's-related proteins, genetic testing, and cognitive performance tests. Together, these show us what is happening in your brain and why.
Read the full answer
We use structural MRI to assess hippocampal volume and cortical thickness, PET scanning to map regional glucose metabolism, and a panel of blood-based biomarkers including p-tau217, neurofilament light chain, homocysteine, BDNF, and inflammatory markers such as IL-6 and TNF-alpha. We also run neurogenomic testing to identify genetic variants that affect amyloid clearance, methylation capacity, and neurotransmitter metabolism. These tests provide a layered picture of brain structure, function, and molecular risk that no single test can deliver on its own.
How is this different from what a standard neurologist would do?+
Most neurologists run a brief memory screening and a standard MRI. We go deeper with blood biomarkers that detect Alzheimer's-related changes years before symptoms become obvious, plus brain imaging that measures how well your brain is actually functioning.
Read the full answer
A standard neurology visit for memory complaints typically involves a brief cognitive screening test such as the MoCA, a structural MRI, and basic blood work. If the MoCA score is above cutoff and the MRI shows no large lesions, the patient is often told to return in six to twelve months. Our evaluation is built around precision biomarkers and functional imaging that detect changes years before standard screening tools flag a problem. We also measure the metabolic and inflammatory drivers behind cognitive decline so that treatment can target root causes rather than manage symptoms.
What treatments are available for cognitive decline?+
We use IV therapies including NAD+, exosomes, and stem cells to restore brain cell energy, reduce inflammation, and support repair. The specific combination depends on what your test results show.
Read the full answer
Our protocols are assembled from several regenerative and metabolic therapies based on each patient's diagnostic results. NAD+ intravenous therapy restores mitochondrial energy output in metabolically compromised neurons. Exosome therapy delivers anti-inflammatory and neurotrophic signaling molecules across the blood-brain barrier. Mesenchymal stem cell therapy supports cellular repair and modulates the neuroinflammatory cascade. These therapies are combined and sequenced during our Intensive Brain Health Program based on what the diagnostics reveal.
How long does the evaluation and treatment program take?+
The main program takes three to five consecutive days. Some patients return for follow-up IV sessions every four to eight weeks depending on how they respond.
Read the full answer
The Intensive Brain Health Program is delivered over three to five consecutive days. During that window, patients complete diagnostic testing, review findings in detail with Dr. Orr, and receive a full course of IV-based and regenerative therapies. Some patients return for follow-up infusion cycles at intervals of four to eight weeks depending on their response and biomarker trajectory. We also provide a long-term maintenance plan that may include oral supplementation through Action Potential Supplements and periodic reassessment.
Can cognitive decline actually be reversed?+
In many cases, yes — especially when caught early. Decline caused by inflammation, nutrient deficiencies, or metabolic problems often responds to targeted treatment. Once dementia has progressed significantly, the window narrows, which is why early evaluation matters.
Read the full answer
The answer depends on the stage and the cause. Cognitive decline driven by chronic neuroinflammation, mitochondrial dysfunction, nutrient deficiency, or hormonal imbalance can often be partially or fully reversed when caught early and treated at the metabolic level. Dr. Dale Bredesen's published case series (2014, Aging) demonstrated measurable cognitive improvement in nine out of ten patients with early cognitive decline using a multi-target protocol. Once decline has progressed to moderate or severe dementia with substantial neuronal loss, the window for reversal narrows considerably. That is why early detection matters more than any single therapy.
Should I bring a family member to the cognitive evaluation appointment?+
Yes, please do. A spouse, adult child, or close friend can describe changes you may not notice yourself, and their observations often affect the diagnosis and treatment plan.
Read the full answer
I recommend it. Cognitive decline often affects a patient's ability to accurately report their own symptoms. A spouse, adult child, or close friend can provide observations about changes in memory, word-finding, navigation, personality, and daily functioning that the patient may not recognize or may understate. The family member's perspective often changes the clinical picture in ways that affect diagnosis and treatment planning.
Can medications I am currently taking be causing my memory problems?+
Yes, several common medications can cause memory problems — including allergy pills like Benadryl, sleep aids, certain blood pressure drugs, and anti-anxiety medications. We review every medication you take as part of the workup.
Read the full answer
This is one of the first things we evaluate, because medication-induced cognitive impairment is both common and reversible. Anticholinergic drugs are the most frequent cause: oxybutynin, diphenhydramine, and certain older antidepressants. Benzodiazepines, opioids, gabapentin, and some blood pressure medications can also impair memory. A 2019 study in JAMA Internal Medicine involving over 280,000 participants found that cumulative anticholinergic exposure was associated with increased dementia risk. We review every medication and supplement as part of the evaluation.
How do you measure whether cognitive function is improving during treatment?+
We use repeat cognitive tests, brain wave mapping, and volumetric MRI to track measurable changes over time. Blood markers tell us whether brain cell injury is continuing or has slowed. These produce objective numbers, not guesswork.
Read the full answer
We use neurocognitive testing that evaluates memory, processing speed, executive function, and attention, providing quantitative scores compared across time points. NeuroQuant volumetric MRI analysis can show whether brain volume loss has stabilized or volume has been regained. Plasma biomarkers such as neurofilament light chain provide a measure of ongoing neuronal injury. These are numbers that either move in the right direction or they do not.
Your Brain Deserves a Real Evaluation
If your memory is changing and no one has measured why, that gap between what you’re experiencing and what your doctors have tested is exactly where we work. Dr. Orr and the team at The Neurogenesis Project are accepting new patients in St. Marys, Georgia.